An early clinical trial in China has reported encouraging results for a new stem cell therapy for heart failure, with nine of the 10 patients involved showing significant improvements in heart function.
Researchers at Nanjing Drum Tower Hospital said the experimental treatment uses patients’ own cells, which are reprogrammed into induced pluripotent stem cells (iPSCs) and then developed into specialized heart muscle cells.
How the Experimental Treatment Works
The researchers converted cells taken from the patients into iPSCs before transforming them into cardiac muscle cells. These cells were then injected into damaged areas of the patients’ hearts.
The approach is designed to help repair damaged heart tissue, encourage the growth of new cardiac muscle cells and improve overall heart function.
Heart failure can cause symptoms including shortness of breath, persistent fatigue, swelling in the legs, rapid weight gain and a continuing cough. For some patients with severe disease, a heart transplant can be an effective treatment, although a shortage of donor organs limits access to transplantation.
Results Remain Preliminary
Researchers reported significant improvements in heart function in nine of the 10 participants. The study also indicated that the therapy may help slow age-related weakening of heart muscle.
However, the findings remain preliminary because the trial involved only 10 patients. Larger clinical studies and longer-term follow-up will be needed to determine the treatment’s effectiveness, safety and potential role in routine heart failure care.
The early results therefore offer a potential avenue for further research rather than establishing the stem cell therapy as a proven or widely available treatment for heart failure.
Also Read :PIMS Medical Facility Inactive — PM Shehbaz Orders Probe
Today's E-Paper